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Trastuzumab was first funded in New Zealand for use in HER2+ve stage I-III breast cancer in 
2007. This observational study aims to ascertain the patterns of use of trastuzumab in women 
with invasive HER2+ve breast cancer, and assess the effectiveness of adjuvant trastuzumab in 
women with stage I-III HER2+ve breast cancer. 
Methods 
The Waikato and Auckland Breast Cancer Registries have clinical details of 12372 women 
diagnosed with invasive breast cancer between June 2000 and May 2013. The proportion of 
women with HER2+ve breast cancer treated with trastuzumab was examined by age, ethnicity, 
stage and year of diagnosis. Differences in outcomes including the development of metastases 
and death were assessed for women with stage I-III HER2+ve breast cancer treated with both 
chemotherapy and trastuzumab, compared to women treated with chemotherapy alone.  
Results 
Among the 1587 HER2+ve breast cancer patients, 888 (56.0%) women received trastuzumab.  
The probability of having trastuzumab decreased with higher age and co-morbidity score and 
increased with year of diagnosis, tumour size and cancer stage. Māori and Pacific women were 
less likely to be treated with trastuzumab.  After adjustment for potential confounding factors the 
treatment with trastuzumab improved breast cancer-specific mortality (adjusted hazard ratio 0.57, 
95% CI: 0.35-0.93). 
Conclusion 
Overall this observational study has shown a substantial improvement in survival for women with 
HER2+ve stage I-III breast cancer, and much of this improvement can be attributed to the 
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introduction of trastuzumab. Changes in chemotherapy also appear to have led to improved 
outcomes. 
 







In New Zealand, the presence of the bio-marker human epidermal growth factor receptor 2 
(HER2) in women with breast cancer has been commonly ascertained since 1998, and routinely 
since 2006. It has been found to be present in approximately 15-20% of breast cancers,(1, 2) 
presenting more commonly in breast cancers of younger women.(3) It is known that women who 
have HER2 positive (+ve) breast cancer have a poorer prognosis compared to women with  HER2 
negative (–ve) disease.(1) 
Trastuzumab (Herceptin®) is a targeted therapy for patients with HER2+ve breast cancer. 
Randomised clinical trials have shown that trastuzumab reduced breast cancer recurrence and 
mortality in women with early stage HER2+ve breast cancer after surgery.(4-8) A study combining 
data from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-31 and North 
Central Cancer Treatment Group (NCCTG) N9831 clinical trials with a median follow-up time of 
8 years, demonstrated a hazard ratio of 0.63 (95% CI: 0.54-0.73) in breast cancer-specific 
mortality and a hazard ratio of 0.60 (95% CI: 0.53-0.68) in all-cause mortality after adding 12 
months trastuzumab to chemotherapy for HER2+ve stage I-III breast cancer.(4) 
Trastuzumab was first licensed by the US FDA (Federal Drug Regulatory Authority) in 1998 for 
metastatic HER2+ve breast cancer and was funded for this indication in New Zealand since 2002 
by PHARMAC, the national pharmaceutical funding agency.(9, 10) In 2006, 12 months of adjuvant 
therapy was licensed by the FDA for the treatment of stage I-III HER2+ve breast cancer.(11) In 
July 2007 PHARMAC also approved trastuzumab for stage I-III breast cancer but only funded 9 
weeks of treatment.(10) From 1 July 2010, trastuzumab was funded for early stage disease for 
treatment of up to 12 months.(12) Trastuzumab for stage I-III HER2+ve breast cancer is only 
funded in conjunction with chemotherapy, either concomitantly with taxane chemotherapy or 
sequentially after chemotherapy.   
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Stage I breast cancer generally has an excellent prognosis. As the early adjuvant trastuzumab 
breast trials included only patients with stage I HER2+ve cancers more than 1cm in size, 
guidelines for adjuvant treatment with trastuzumab may not apply to stage 1 HER2+ve tumours 
smaller than 1cm.(6, 13) Stage II and III HER2+ve breast cancers are associated with a 
progressively poorer prognosis and greater risk of recurrence and these women should be offered 
trastuzumab as part of their adjuvant therapy (4, 5), as should women with metastatic HER2+ve 
breast cancers. 
This study aims to 1) ascertain the patterns of use of trastuzumab in women with invasive 
HER2+ve breast cancer in New Zealand, 2) compare clinical outcomes between women with 




The combined Waikato and Auckland Breast Cancer Registers have clinical details of 12372 
women diagnosed with invasive breast cancer between June 2000 and May 2013. Men diagnosed 
with breast cancer are included in the registers but were not included in this study. The collected 
information in the combined registers includes (but is not limited to): 1) patient characteristics: 
age and ethnicity; 2) tumour biology: diagnosis date, cancer stage, grade, tumour size, oestrogen 
receptor (ER), progesterone receptor (PR) and HER2 status; 3) treatment: chemotherapy, 
trastuzumab, endocrine therapy, surgery and radiotherapy; and 4) cancer progression: 
metastases, date of death and cause of death. The presence of comorbidities was ascertained 
by data linkage to the National Minimum Dataset (NMDS) that records clinical data for inpatients 
and day patients.  
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Mortality information including date of death and cause of death were from both the combined 
registers and New Zealand national mortality collection. The mortality collection is maintained by 
the Ministry of Health and records all deaths in New Zealand. Ethical approval for the study was 
granted through the Northern A Health and Disability Ethics Committee, reference: 
12/NTA/42/AM01. 
 
Pattern of trastuzumab use in HER2+ve invasive breast cancers 
Of this group, 9504 female breast cancers (76.8%) were tested for HER2 receptor status, and 
1587 (16.7%) invasive breast cancers were HER2+ve (FISH amplified or IHC 3+). The usage of 
trastuzumab for HER2+ve breast cancer was examined by age, year of diagnosis, ethnicity and 
cancer stage at diagnosis. The differences between subgroups were explored by chi-square test 
and logistic regression. 
 
Outcomes in women with stage I-III HER2+ve breast cancer treated with trastuzumab 
Trastuzumab is only funded in conjunction with chemotherapy for stage I-III HER2+ve breast 
disease in New Zealand. The benefit of trastuzumab for women with HER2+ve stage I-III breast 
cancer was explored by comparing the clinical outcomes of women treated with chemotherapy 
and trastuzumab (adjuvant and/or neo-adjuvant trastuzumab) and women treated with 
chemotherapy but without trastuzumab. The studied cohort included women diagnosed with stage 
I-III HER2+ve breast cancer at the age of less than 75 years, with a tumour size equal to or larger 
than 1cm.(6, 13) Patients who had inflammatory breast cancer, or developed metastatic disease 
or local recurrence within 3 months of diagnosis were excluded. Eligible women who received 
chemotherapy without trastuzumab for their primary breast cancer within 12 months of cancer 
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diagnosis were considered to be the control group (chemotherapy only group: 275 women), and 
women who started chemotherapy and trastuzumab for their primary breast cancer within 12 
months of cancer diagnosis were considered to be the intervention group (trastuzumab treated 
group: 604 women). The characteristics of women in these two groups were studied. 
Kaplan-Meier method and Cox proportional hazards model were used to examine the breast 
cancer-specific survival, all-cause survival and metastasis-free survival between women in the 
chemotherapy only group and women in the trastuzumab treated group. For all-cause survival 
analyses, patients without mortality information were considered to be censored on the last 
updated date for Mortality Collection which was 31 December 2014. For cancer-specific analyses, 
deaths from other causes were censored on the date of death. The censor date for metastasis-
free survival was the last follow-up date for an individual patient in the Waikato and Auckland 
Breast Cancer Registers.  
In the Cox proportional hazards model, hazard ratios between the chemotherapy only group and 
the trastuzumab treated group were estimated after adjustment for age, ethnicity, comorbidity (we 
applied a C3 score retrospectively to breast cancer patients (14)), stage, grade, tumour size, 
ER/PR status (ER and PR negative, ER and/or PR positive), endocrine therapy, surgery type 
(mastectomy, breast conserving surgery, no primary surgery), radiotherapy and chemotherapy. 
The chemotherapy regimens were classified into four groups: 1) anthracycline and taxane based, 
2) anthracycline based, 3) taxane based and 4) non-anthracycline and non-taxane based.  
 
Outcomes in women treated with 9 weeks and 12 months of trastuzumab 
Trastuzumab is expensive and not without side effects. If a shorter treatment is equivalent with 
regards outcomes then it will be more cost effective. New Zealand was unique in approving a 9 
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week course of treatment which resulted in a natural experiment. While we are underpowered to 
“prove” equivalence we believe it is worthwhile reporting the observational findings. Thus we 
explored the difference in breast cancer-specific survival between women in the intervention 
group who received 9 weeks (22-126 days: 175 women) of trastuzumab and women who received 
12 months (316-441 days: 342 women) of trastuzumab. Five women who received trastuzumab 
for less than 3 weeks, 27 women who had trastuzumab for 127-315 days, and 55 women on 
trastuzumab for more than 442 days were not included in this analysis. The survival difference 
between subgroups was considered significant if the two-tailed p-value was less than 0.05. All 
data analyses were performed in IBM SPSS statistics 23 (New York, United States). 
 
Results 
Pattern of trastuzumab use in HER2+ve invasive breast cancers 
Among the 1587 patients with HER2+ve breast cancer, 888 (56.0%) women had trastuzumab in 
2000-2013 (Table 1). The probability of having trastuzumab decreased with higher age (from 
68.7% for women aged <50 to 5.8% for women aged 75+ years) and co-morbidity score (from 
60.7% for C3 score 0 to 30.3% for C3 score 2+), increased with tumour size (from 45.0% for 
tumour size <10 mm to 62.3% for tumour size 30+ mm) and cancer stage (from 46.8% for stage 
I to 66.6% for stage III) except stage IV (51.5%). In 2000-2006, 30.4% of women diagnosed with 
HER2+ve breast cancer received trastuzumab, compared to 72.3% of women with HER2+ve 
disease diagnosed in 2007-2013. The chi-square test showed no significant difference in the 
treatment with trastuzumab between Māori women (50.5%), Pacific women (49.7%) and others 
(57.6%). However, after adjustment for age, cancer stage, grade, year of diagnosis, tumour size 
and C3 score, the respective odds ratios of Māori women (184) and Pacific women (171) having 
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trastuzumab compared to others (1232) were 0.44 (95% CI: 0.29-0.67) and 0.31 (95% CI: 0.20-
0.50). 
 
Outcomes in women with HER2+ve stage I-III breast cancer treated with trastuzumab 
Of the 1455 women with HER2+ve stage I-III breast cancer, 27 developed metastatic disease or 
local recurrence in less than 3 months of initial diagnosis, 2 had inflammatory breast cancer, 185 
had a tumour size less than 10mm, and 103 women were 75+ years old (Figure 1). These 317 
women were excluded from further analyses. A total of 275 women who received chemotherapy 
without trastuzumab for their primary breast cancer within 12 months of cancer diagnosis were 
included in the chemotherapy only group, and 604 women who received chemotherapy and 
trastuzumab were included in the trastuzumab treated group. The rest of women were not 
included either because they did not start chemotherapy for primary breast cancer in no more 
than 12 months of initial diagnosis (237), or because they started trastuzumab in more than 12 
months of initial diagnosis (18) or the start date of trastuzumab was not available (4). 
Over 90% women in the chemotherapy only group were diagnosed in 2000-2006, and 90% 
women in the trastuzumab treated group were diagnosed in 2007-2013 (Table 2). In the 
trastuzumab treated group, 559 (92.5%) women received trastuzumab in 2007-2013, and 45 
(7.5%) women received trastuzumab in 2000-2006. There was no significant difference in age 
between the chemotherapy only group and the trastuzumab treated group. The trastuzumab 
treated group has a higher proportion of stage I breast cancers, a lower proportion of Māori 
patients, and a lower proportion of ER and PR negative cancers than the chemotherapy only 
group. The majority (73.5%) of women in the chemotherapy only group received anthracycline 
based chemotherapy while 86.3% of women in the trastuzumab treated group received both 
anthracycline and taxane based chemotherapy. Anthracycline based chemotherapy was more 
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commonly used in the early years, anthracycline and taxane based chemotherapy was more 
commonly used in recent years (Appendix Table 1). 
The median follow-up time was 107 months for women in the chemotherapy only group and 53 
months for women in the trastuzumab treated group. Breast cancer-specific survival, all-cause 
survival and metastases free survival in the trastuzumab treated group were all significantly better 
(log-rank test: p-values all less than 0.001) (Figure 2, Appendix Table 2). The unadjusted hazard 
ratios in breast cancer-specific mortality, all-cause mortality and metastases- (distant 
recurrences) in the trastuzumab treated group compared to the chemotherapy only group were 
0.44, 0.48 and 0.56, respectively (Table 3). After adjustment for age, ethnicity, comorbidity score, 
stage, grade, tumour size, ER/PR status, endocrine therapy, surgery type, radiotherapy and 
chemotherapy regimens (in particular to allow for the effect of adding taxanes to the 
chemotherapy regimen), the hazard ratios changed to 0.58, 0.65 and 0.66, respectively. The 
adjusted hazard ratio of breast cancer-specific mortality for women who received anthracycline 
and taxane based chemotherapy was 0.60 (95% CI: 0.36-0.99) compared to women who received 
anthracycline based chemotherapy. 
 
Outcomes in women treated with 9 weeks and 12 months of trastuzumab 
Women (175) who received 9 weeks of trastuzumab were older and diagnosed in earlier years 
than women (342) who received 12 months of trastuzumab (Appendix Table 3). There were no 
significant differences in age, ethnicity, cancer stage, ER/PR status or chemotherapy regimens 
between these two groups. 54.9% of women in the 9 weeks treatment group were diagnosed in 
2006-2009 and 64.3% of women in the 12 months treatment group were diagnosed in 2010-2013. 
The Kaplan-Meier analysis showed no significant difference in breast cancer-specific survival 
between women receiving 9 weeks of trastuzumab and women receiving 12 months of 
trastuzumab (Appendix Figure 1, log-rank test p-value: 0.246). The adjusted hazard ratios in 
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breast cancer-specific mortality and all-cause mortality in women receiving 12 months of 
trastuzumab were 0.62 (95% CI: 0.29-1.30, p-value=0.202) and 0.52 (95% CI: 0.25-1.07, p-
value=0.074) compared to women receiving 9 weeks of trastuzumab, respectively. 
 
Discussion 
Since funding of adjuvant trastuzumab in conjunction with chemotherapy was approved for 
HER2+ve stage I-III breast cancer in New Zealand, it has become widely used. Sixty nine percent 
of women with HER2+ve non-metastatic breast cancer were treated with trastuzumab between 
2007 and 2013. The use of trastuzumab varied by age, cancer stage and ethnicity. Older women 
were less likely to be treated with chemotherapy and trastuzumab, while women with more 
advanced disease were more likely to receive adjuvant trastuzumab. Within ethnic groups, 
although the sample size is relatively small, Māori and Pacific women were less likely to receive 
neo-adjuvant/adjuvant trastuzumab and chemotherapy.  Māori and Pacific women tend to be 
younger, have more advanced disease and are more likely to have comorbidities. After 
adjustment for these factors we have shown that both groups are less likely to be treated with 
trastuzumab than are other New Zealanders. This apparent differential use of a potentially life-
saving treatment needs further research to better understand this inequity.  
Our study suggests that outcomes for women with HER2+ve breast cancer have improved. 
Although expensive, the introduction of trastuzumab has provided a substantial benefit to women 
with HER2+ve early stage disease with 5-year breast cancer-specific survival improving from 
75.6% to 89.5% (adjusted hazard ratio: 0.58). This is in line with the NSABP B-31 and the NCCTG 
N9831 clinical trials demonstrating a 0.60 hazard ratio in breast cancer-specific mortality by 
adding 12 months trastuzumab to chemotherapy for HER2+ve stage I-III breast cancer after a 
median follow-up time of 8 years.(4) We have shown that during this time there has also been a 
change in the chemotherapy regime for women with stage I-III breast cancer with more women 
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being treated with combined anthracycline and taxane based treatment. This has led to further 
reductions in mortality with an adjusted HR of 0.60 compared to the mortality in women treated 
with only anthracycline based chemotherapy. 
The Finland Herceptin (FinHer) trial(15) showed a 35% relative reduction in rates of distant 
disease using 9 weeks of trastuzumab compared to no trastuzumab. As noted above in New 
Zealand only 9 weeks of trastuzumab was funded for women with non-metastatic breast cancer 
between 2007 and 2010. When we compared the survival between women treated with 9 weeks 
of trastuzumab and women treated with 12 months of trastuzumab, no significant difference was 
identified, with an adjusted HR of 0.62 (95% CI 0.29 – 1.30). This may be because our study was 
underpowered to show a difference and further research is needed to demonstrate whether there 
is a worthwhile benefit of 12 months treatment over 9 weeks. A 9-week course of trastuzumab is 
associated with a smaller risk of side effects and lower costs.(16, 17) but if this regime is 
significantly less effective, then the 12 month course should be preferred. The results of the SOLD 
trial, which has been powered to compare 9 weeks with 12 months of trastuzumab are eagerly 
awaited.(18) 
The strength of this study is that it is based on real world data. The patients in clinical trials are 
highly selected and may not represent the diversity of patients who may benefit from trastuzumab. 
This study is based on the Waikato and Auckland population-based Breast Cancer Registers that 
collect good quality data on all breast cancer patients. The data have been shown to be highly 
complete and accurate.(19) The limitations of this study are associated with the nature of an 
observational study. The characteristics of patients in the chemotherapy only group and those in 
the trastuzumab treated group are not evenly distributed. Although we adjusted for a number of 
factors in the multivariate analyses, there may be still some residual confounding. However, our 
findings are in line with the large randomized trials.(4-8) and support the belief that the use of 





Overall this observational study has shown a substantial improvement in survival for women with 
HER2+ve stage I-III breast cancer, and this improvement can be attributed to the treatment of 
trastuzumab. Changes in chemotherapy also appear to have led to improved outcomes. Further 
research is needed to establish the benefit of 12 months treatment of trastuzumab over 9 weeks.  
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Figure 2. Breast cancer-specific survival between the chemotherapy only group and the 




Table 1. The treatment pattern of trastuzumab in HER2+ve breast cancers 
 Total No Trastuzumab 
Had 
Trastuzumab Unadjusted Odds Ratio Adjusted Odds Ratio 
Age       
<50 616 193 423 68.7% Ref Ref 
50-59 477 189 288 60.4% 0.70 (0.54-0.89)** 0.53 (0.39-0.74)*** 
60-74 374 204 170 45.5% 0.38 (0.29-0.50)*** 0.23 (0.16-0.34)*** 
75+ 120 113 7 5.8% 0.03 (0.01-0.06)*** 0.01 (0.01-0.03)*** 
Ethnicity       
Others 1232 522 710 57.6% Ref Ref 
Māori 184 91 93 50.5% 0.75 (0.55-1.02) 0.44 (0.29-0.67)*** 
Pacific 171 86 85 49.7% 0.73 (0.53-1.00) 0.31 (0.20-0.50)*** 
Cancer stage      
I 462 246 216 46.8% Ref Ref 
II 574 249 326 56.8% 1.49 (1.16-1.90)** 1.87 (1.28-2.72)** 
III 419 140 278 66.3% 2.27 (1.73-2.98)*** 3.37 (2.17-5.22)*** 
IV 132 64 68 51.5% 1.21 (0.82-1.78) 2.86 (1.38-5.91)** 
Grade       
1 52 38 14 26.9% Ref Ref 
2 554 285 269 48.6% 2.56 (1.36-4.83)** 3.62 (1.63-8.03)** 
3 914 336 578 63.2% 4.67 (2.49-8.74)*** 6.96 (3.14-15.44)*** 
Unknown 67 40 27 40.3% - - 
Tumour size      
<10 mm 189 104 85 45.0% Ref Ref 
10~30 mm 791 347 444 56.1% 1.57 (1.14-2.15)** 2.17 (1.40-3.38)*** 
30+ mm 517 195 322 62.3% 2.02 (1.44-2.83)*** 1.91 (1.12-3.28)* 
Unknown 90 53 37 41.1% - - 
C3 score       
0 1279 503 776 60.7% Ref Ref 
1 133 74 59 44.4% 0.52 (0.36-0.74)*** 0.89 (0.55-1.44) 
2+ 175 122 53 30.3% 0.28 (0.20-0.40)*** 0.41 (0.25-0.68)*** 
Year of diagnosis      
2000-06 619 431 188 30.4% Ref Ref 
2007-13 968 268 700 72.3% 5.99 (4.80-7.47)*** 15.24 (11.13-20.86)*** 
       
Total 1587 699 888 56.0%   
* p-value<0.05, ** p-value<0.01, *** p-value<0.001 
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Table 2. Characteristics of women in the chemotherapy only group and women in the 










Age (years) Mean: 49.6; Median: 50 Mean: 50.3; Median: 50    
<40 50 18.2% 88 14.6% 0.072 138 15.7% 
40-49 80 29.1% 196 32.5%  276 31.4% 
50-59 105 38.2% 197 32.6%  302 34.4% 
60-69 36 13.1% 117 19.4%  153 17.4% 






Year of diagnosis       
2000-2003 95 34.5% 17 2.8% <0.001 112 12.7% 
2004-2006 154 56.0% 44 7.3%  198 22.5% 
2007-2009 19 6.9% 220 36.4%  239 27.2% 
2010-2013 7 2.5% 323 53.5%  330 37.5% 
        
Ethnicity       
Māori 43 15.6% 61 10.1% 0.036 104 11.8% 
Pacific 30 10.9% 56 9.3%  86 9.8% 
Others 202 73.5% 487 80.6%  689 78.4% 
 
       
Cancer stage        
Stage I 44 16.0% 141 23.3% 0.046 185 21.0% 
Stage II 131 47.6% 260 43.0%  391 44.5% 
Stage III 100 36.4% 203 33.6%  303 34.5% 
        
ER/PR status        
ER and PR negative 131 47.6% 240 39.7% 0.002 371 42.2% 
ER and/or PR 
positive 
141 51.3% 364 60.3%  505 57.5% 
Unknown 3 1.1% 0 0.0%  3 0.3% 
        
Chemotherapy       
Anthracycline and 
taxane based 48 17.5% 521 86.3% <0.001 569 64.7% 
Anthracycline based 202 73.5% 37 6.1%  239 27.2% 




20 7.3% 1 0.2%  21 2.4% 
Unknown 1 0.4% 1 0.2%  2 0.2% 
        





Table 3. Hazard ratios in the trastuzumab treated group compared to the chemotherapy only 
group estimated with Cox proportional hazards model 
 Unadjusted hazard ratio P value 
Adjusted 
hazard ratio† P value 
Breast cancer-specific mortality 






All-cause mortality using end of 






Metastases using last follow-up 






† Adjusted for age, ethnicity, C3 score, stage, grade, tumour size, ER/PR status, endocrine 



















2000-2003 8 7.1% 82 73.2% 6 5.4% 15 13.4% 1 112 
2004-2006 58 29.3% 133 67.2% 3 1.5% 4 2.0% 0 198 
2007-2009 206 86.2% 13 5.4% 17 7.1% 2 0.8% 1 239 
2010-2013 297 90.0% 11 3.3% 22 6.7% 0 0.0% 0 330 
Total 569 64.7% 239 27.2% 48 5.5% 21 2.4% 2 879 
 
Appendix Table 2. 5-year clinical outcomes between the chemotherapy only group and the 
trastuzumab treated group 
 
Chemotherapy only group Trastuzumab treated group P value  (Log rank test)  
Breast cancer-specific survival        
75.6% (70.5% - 80.7%) 
 
89.5% (86.6% - 92.5%) 
 
<0.001           
All-cause survival      
 
 74.6% (69.4% - 79.8%)  88.2% (85.0% - 91.3%) 
 
<0.001     
 
     
Metastases-free survival using last follow-up date as censor date 
 72.6% (67.3% - 77.9%)  83.0% (79.4% - 86.7%) 
 
<0.001     
 





Appendix Table 3. Characteristics of women receiving 9 weeks of trastuzumab and women 
receiving 12 months of trastuzumab 
 
Women receiving 9 weeks 
trastuzumab 




Age (years)    
<40 19 10.9% 54 15.8% 0.061 
40-49 47 26.9% 119 34.8%  
50-59 62 35.4% 102 29.8%  
60-69 44 25.1% 65 19.0%  





Year of diagnosis     
2000-2003 0 0.0% 14 4.1% <0.001 
2004-2006 12 6.9% 19 5.6%  
2007-2009 96 54.9% 89 26.0%  
2010-2013 67 38.3% 220 64.3%  
      
Ethnicity     
Māori 19 10.9% 33 9.6% 0.868 
Pacific 15 8.6% 27 7.9%  
Others 141 80.6% 282 82.5%  
      
Cancer stage      
Stage I 45 25.7% 76 22.2% 0.674 
Stage II 75 42.9% 154 45.0%  
Stage III 55 31.4% 112 32.7%  
      
ERPR status      
ER and PR negative 73 41.7% 132 38.6% 0.493 
ER and/or PR 
positive 102 58.3% 210 61.4%  
      
Chemotherapy     
Anthracycline and 
taxane based 147 84.0% 303 88.6% 0.068 
Anthracycline based 8 4.6% 20 5.8%  
Taxane based 20 11.4% 18 5.3%  
Non-anthracycline 
and non-taxane 0 0.0% 1 0.3%  
      









Follow-up time (months) 0 12 24 36 48 60 72 84 96 108 120 
Number of 
women at risk 
9 weeks 175 174 164 142 119 99 85 55 12 4 1 
12 months 342 342 304 235 173 118 69 38 31 18 13 
 
Appendix Figure 1. Breast cancer-specific survival between women receiving 9 weeks of 
trastuzumab and women receiving 12 months of trastuzumab by Kaplan-Meier method 
 
 
 
